Covidien Surgical Device Sales Growth Of 10.5% Is Driven By Laparoscopy
This article was originally published in The Gray Sheet
Executive Summary
Newly independent medical technology firm Covidien's surgical device sales growth of 10.5% for the quarter ended June 29 was driven by demand for autosuture laparoscopic instruments in the United States and Europe, the company reported during its fiscal third-quarter earnings call Aug. 9
You may also be interested in...
Covidien Faces Challenge Of Accelerating Growth After Spin-Off From Tyco
Newly independent medical technology firm Covidien plans select acquisitions and divestitures as well as increased licensing activity to help accelerate growth following its June 29 spin-off from parent company Tyco International
Tyco Acquires Bio-Sealant Pipeline With $245 Mil. Confluent Surgical Buy
Tyco Healthcare subsidiary U.S. Surgical will acquire Confluent Surgical for $245 mil. to augment its suture business with a pipeline of bioabsorbable sealants
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”